MCM
PBYI icon

Manchester Capital Management’s Puma Biotechnology PBYI Stock Holding History

Manchester Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-199
Closed -$8K – 620
2019
Q1 		$8K Buy
+199
New +$6.08K ﹤0.01% 578
2015
Q1 		– Sell
-1,042
Closed -$197K – 774
2014
Q4 		$197K Hold
1,042
– – 0.02% 365
2014
Q3 		$249K Sell
1,042
-623
-37% -$128K 0.03% 300
2014
Q2 		$110K Buy
1,665
+642
+63% +$45.7K 0.01% 534
2014
Q1 		$107K Buy
+1,023
New +$120K 0.02% 512

Other funds holding PBYI

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Manchester Capital Management's PBYI Position: Q2 2019 in Review

Manchester Capital Management sold out of Puma Biotechnology (PBYI) in Q2 2019, closing a stake of 199 shares — an estimated $8K sold.

Manchester Capital Management first reported a position in PBYI in Q1 2014 and held it in 5 quarters. The position peaked at $249K in Q3 2014. 139 funds tracked by Wall St. Rank hold PBYI as of Q2 2019.

  • Manchester Capital Management reported no remaining Puma Biotechnology position as of Q2 2019 after selling out during the quarter.
  • Manchester Capital Management sold 199 Puma Biotechnology shares in Q2 2019, an estimated $8K.
  • Manchester Capital Management first reported a position in Puma Biotechnology in Q1 2014 and held it in 5 quarters.
  • Manchester Capital Management's Puma Biotechnology position peaked at $249K in Q3 2014.
  • 139 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2019.

Based on Manchester Capital Management's 13F filing for Q2 2019, filed 5 Aug 2019.